Bausch + Lomb acquire Technolas Perfect Vision

November 19, 2012

Article

Bausch + Lomb will purchase all outstanding shares of leading ophthalmic laser company Technolas Perfect Vision.

The companies, who entered into a co-promotion agreement in September 2011, will close the acquisition deal by the end of January 2013.

In earlier collaborations the companies have heavily promoted and further advanced the VICTUS femtosecond laser. The last twelve months has seen the VICTUS platform receive marketing approval from authorities in Europe and the US.

Dr Kristian Hohla, CEO of Technolas Perfect Vision, stated, "Our systems for refractive and cataract procedures complement Bausch + Lomb’s surgical portfolio and will help accelerate our expansion into the faster growing segments of the ocular surgery market. Together, we’ve proven our ability to introduce and market the highly innovative and differentiated VICTUS Femtosecond Laser Platform, and we look forward to working with our Bausch + Lomb colleagues to further advance ocular surgery using other laser-based technologies.”

John Barr, executive vice president and president of Bausch + Lomb Surgical, commented, "Our goal is to provide a compelling choice of products to fit the specific needs of their practice and patients. We intend to continue to invest in development and clinical programs that build upon their strong leadership position in laser-based surgical platforms. We look forward to working with Kristian and his team to provide physicians with systems that improve a wide range of sight-enhancing surgeries."

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!

Recent Videos

At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients

Early intervention is crucial for long-term outcomes in paediatric gene therapy

$At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery$

Robert Ang, MD, explains why a small-aperture IOL is "not a niche product"

Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.

ARVO 2025: Ocular and systemic mitochondrial diseases may be key to dementia diagnosis

Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).

ARVO 2025: Alfredo Sadun, MD, PhD, says "later is better" for some LHON interventions

At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.

ARVO 2025: Nitish Mehta, MD, provides real-world insights from aflibercept 8 mg for treatment-naive diabetic macular oedema

ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy

ARVO 2025: Anat Loewenstein, MD, and colleagues on meeting needs of patients with diabetic retinopathy

$At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study$

Sheng Lim, MD, FRCOphth, brings data from the CONCEPT study to the ASCRS meeting